We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going?
Read MoreHide Full Article
Key Takeaways
Oscar Health shares gained 14.9% in three months, supported by strong membership growth and improved margins.
OSCR's membership surged 46.2% to 2.96 million, while its first-half medical loss ratio improved to 75%.
Oscar's SG&A ratio fell to 14.7% from 17.2%, aided by technology efficiencies and disciplined cost management.
Oscar Health, Inc. (OSCR - Free Report) shares have gained 14.9% in the past three months, outpacing the broader market. The advance has coincided with rapid membership growth, better medical economics and lower administrative expense ratios.
The next test is execution. Oscar must sustain share gains and underwriting discipline while navigating Affordable Care Act (ACA) market contraction, membership cleanup, seasonality and a valuation that already reflects higher expectations.
Oscar's Share Gains Strengthen the Bull Case
Oscar ended the second quarter of 2026 with 2.96 million members, up 46.2% year over year. That growth came even as broader ACA membership declined about 12%, indicating substantial share capture in a contracting market.
Oscar's first-half 2026 medical loss ratio improved to 75% from 83% a year earlier. Management attributed the improvement to disciplined pricing, stronger current-year performance and favorable prior-period reserve development.
That mix matters because membership growth is more valuable when medical costs remain controlled. Oscar expects a full-year 2026 medical loss ratio of 81%-82%, implying a higher second-half cadence but still reflecting better economics than the prior-year first half.
Oscar's Tech Leverage Adds Margin Support
The first-half selling, general and administrative ratio fell to 14.7% from 17.2%. Fixed-cost leverage, disciplined expense management and technology-driven efficiencies helped expenses grow more slowly than the membership base.
Oscar also reported 98.7% first-pass claims accuracy, with most claims processed in under 48 hours. Artificial intelligence initiatives across benefits, billing, claims, clinical care and member support could add further scalability without proportionate headcount growth.
The Zacks Consensus Estimate for 2026 and 2027 EPS represents an increase of 208.3% and 21% respectively.
Image Source: Zacks Investment Research
Oscar's Ratings Back Growth but Momentum Is Mixed
The three-month advance can continue if Oscar converts share gains into durable underwriting and operating leverage.
Oscar currently carries a Zacks Rank #1 (Strong Buy), which reflects favorable near-term earnings-estimate revision trends. It also has a VGM Score of A, Growth Score of A and Value Score of B, all favorable readings under the Style Score framework.
The Momentum Score of C is less supportive than an A or B and tempers the picture after the recent price gain. Continued fundamental execution therefore remains important even with a top Zacks Rank and favorable overall Style Scores.
The Zacks Consensus Estimate for 2026 earnings of Elevance Health has moved north in the last 30 days while that for UnitedHealth witnessed no movement in the same time frame.
In terms of share price movement, Elevance Health and UnitedHealth Group have lost 1.1% and 11%, respectively, in the past three months.
View the Zacks #1 Rank List
Image: Shutterstock
Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going?
Key Takeaways
Oscar Health, Inc. (OSCR - Free Report) shares have gained 14.9% in the past three months, outpacing the broader market. The advance has coincided with rapid membership growth, better medical economics and lower administrative expense ratios.
The next test is execution. Oscar must sustain share gains and underwriting discipline while navigating Affordable Care Act (ACA) market contraction, membership cleanup, seasonality and a valuation that already reflects higher expectations.
Oscar's Share Gains Strengthen the Bull Case
Oscar ended the second quarter of 2026 with 2.96 million members, up 46.2% year over year. That growth came even as broader ACA membership declined about 12%, indicating substantial share capture in a contracting market.
OSCR's Pricing Discipline Lifts Underwriting Quality
Oscar's first-half 2026 medical loss ratio improved to 75% from 83% a year earlier. Management attributed the improvement to disciplined pricing, stronger current-year performance and favorable prior-period reserve development.
That mix matters because membership growth is more valuable when medical costs remain controlled. Oscar expects a full-year 2026 medical loss ratio of 81%-82%, implying a higher second-half cadence but still reflecting better economics than the prior-year first half.
Oscar's Tech Leverage Adds Margin Support
The first-half selling, general and administrative ratio fell to 14.7% from 17.2%. Fixed-cost leverage, disciplined expense management and technology-driven efficiencies helped expenses grow more slowly than the membership base.
Oscar also reported 98.7% first-pass claims accuracy, with most claims processed in under 48 hours. Artificial intelligence initiatives across benefits, billing, claims, clinical care and member support could add further scalability without proportionate headcount growth.
The Zacks Consensus Estimate for 2026 and 2027 EPS represents an increase of 208.3% and 21% respectively.
Image Source: Zacks Investment Research
Oscar's Ratings Back Growth but Momentum Is Mixed
The three-month advance can continue if Oscar converts share gains into durable underwriting and operating leverage.
Oscar currently carries a Zacks Rank #1 (Strong Buy), which reflects favorable near-term earnings-estimate revision trends. It also has a VGM Score of A, Growth Score of A and Value Score of B, all favorable readings under the Style Score framework.
The Momentum Score of C is less supportive than an A or B and tempers the picture after the recent price gain. Continued fundamental execution therefore remains important even with a top Zacks Rank and favorable overall Style Scores.
Other Stocks to Consider
Elevance Health, Inc. (ELV - Free Report) and UnitedHealth Group (UNH - Free Report) are two other top-ranked stocks. Both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for 2026 earnings of Elevance Health has moved north in the last 30 days while that for UnitedHealth witnessed no movement in the same time frame.
In terms of share price movement, Elevance Health and UnitedHealth Group have lost 1.1% and 11%, respectively, in the past three months.